.ANALYSIS EMPHASIZE.16 Oct 2024. In the NIAGARA hearing, the addition of perioperative durvalumab to common therapy for muscle-invasive bladder cancer improved event-free as well as in general survival, denoting a brand new treatment alternative for this health condition.